Biomol Ther.  2024 Jul;32(4):424-431. 10.4062/biomolther.2023.197.

Engineered T Cell Receptor for Cancer Immunotherapy

• Lee SW
• Lee HM

• KMID: 2557190
• DOI: http://doi.org/10.4062/biomolther.2023.197

Abstract

Among the therapeutic strategies in cancer immunotherapy—such as immune-modulating antibodies, cancer vaccines, or adoptive T cell transfer—T cells have been an attractive target due to their cytotoxicity toward tumor cells and the tumor antigen-specific binding of their receptors. Leveraging the unique properties of T cells, chimeric antigen receptor-T cells and T cell receptor (TCR)-T cells were developed through genetic modification of their receptors, enhancing the specificity and effectiveness of T cell therapy. Adoptive cell transfer of chimeric antigen receptor-T cells has been successful for the treatment of hematological malignancies. To expand T cell therapy to solid tumors, T cells are modified to express defined TCR targeting tumor associated antigen, which is called TCR-T therapy. This review discusses anti-tumor T cell therapies, with a focus on engineered TCR-T cell therapy. We outline the characteristics of TCR-T cell therapy and its clinical application to non-hematological malignancies.

Keyword

Cancer immunotherapy; CAR-T cell; TCR-T cell; Solid tumor